期刊
NATURE MEDICINE
卷 25, 期 4, 页码 547-553出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41591-019-0412-8
关键词
-
资金
- NIH/National Institute of Allergy and Infectious Diseases Grant [U01AI129825]
- Einstein-Rockefeller-CUNY Center for AIDS Research [1P30AI124414-01A1]
- BEAT-HIV Delaney grant [UM1 AI126620]
- Heisenberg-Program of the DFG [KL 2389/2-1]
- European Research Council [ERC-StG639961]
- German Center for Infection Research (DZIF)
- Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) grants [OPP1092074, OPP1124068]
- NIH [1UM1 AI100663, R01AI-129795]
- Robertson fund
Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART interruption almost invariably leads to rebound viremia in infected individuals due to a long-lived latent reservoir of integrated proviruses. Therefore, ART must be administered on a life-long basis. Here we review recent preclinical and clinical studies suggesting that immunotherapy may be an alternative or an adjuvant to ART because, in addition to preventing new infections, anti-HIV-1 antibodies clear the virus, directly kill infected cells and produce immune complexes that can enhance host immunity to the virus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据